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We present a clinical image of a 32-year-old man with 
obesity grade III admitted to our clinic to rule out sec-
ondary causes of obesity. The patient’s body mass index 
(BMI) was 78 kg/m². The beginning of weight gain oc-
curred in his early childhood. The patient has not been 
doing regular physical activities for many years. He was 
diagnosed with hypothyroidism a year before presen-
tation, well-controlled with levothyroxine 50 mcg. On 
admission, his blood pressure was 145/92 mm Hg, and 
his heart rate was 80 bpm. Based on 24-hour ambulatory 
blood pressure monitoring, first-degree arterial hy-
pertension was recognised. The laboratory test results 
(oral glucose tolerance test, HbA1c, fasting insulin, lipids 
profile, TSH, 1 mg dexamethasone test, cortisol profile, 
24-hour urinary free cortisol exertion) were within the 
reference range. Abdominal ultrasonography revealed 
liver steatosis, but, surprisingly, his adipose tissue 
measurements showed no features of visceral obesity. 
Based on the above, the patient’s subtype of obesity 
was defined as “metabolically healthy obesity” (MHO).
We determined the patient’s body composition 
using the bioimpedance technique (Inbody 370). The 
measurement was done two times. The patient’s height 
was 166 cm with a total body mass (TBM) of 215.6 kg. 
TBM consisted of 124 kg of fatty tissue and 91.6 kg of 
fat-free mass. The total body water (69.5 l), protein (18.1 
kg), and minerals (4.00 kg) were out of range. The body 
fat percentage was 57.5%, but, surprisingly, the visceral 
fat level was 1 — the lowest value on the measurement 
scale. The patient’s resting metabolic rate has been 
estimated at 2348 kcal. 
Excess body weight is estimated to affect nearly 2 
billion people. It has accounted for approximately 
4 million deaths and 120 million disability-adjusted 
life years. Obesity is the main risk factor for coronary 
heart disease, hypertension, hyperlipidaemia, and type 
2 diabetes mellitus (T2D). Obesity is also connected with 
an increased risk of certain cancers [1]. Contradictory 
in our case, we present that not every obese patient 
has to be diagnosed with these comorbidities. The 
Adult Treatment Panel-III (ATP-III) criteria characterise 
metabolically unhealthy obesity (MUHO) and MHO. 
These two types of obesity have different features in 
their aetiologies and treatments, which may implicate 
a higher risk for cardiovascular complications among 
MUHO patients in comparison with MHO patients [2, 
3]. However, although in the case of this MHO patient 
the risk of developing cardiovascular complications is 
lower, we should be aware of the risks associated with 
sarcopaenic obesity. Extremely obese patients tend to 
avoid physical activity, which, together with hormonal 
changes and inflammation, can lead to sarcopaenia. 
Sarcopaenic obesity is connected with a higher risk of 
metabolic syndrome, T2D, and atherosclerosis in com-
parison to sarcopaenia alone or simple obesity [4]. The 
patient remains in our outpatient clinic, and regular 
three-month follow-up visits are scheduled.
The aim of our paper was to present the extremely dif-
ferent features and goals in the treatment of obesity, 
which is, in our opinion, unfairly perceived as “a cos-
metics defect”. 
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Figure 1. a. Patient in a coronal plane — front. B. Patient in a coronal plane — back; C. Patient in a sagittal plane; D. Stretch marks 
on the patient’s abdomen; e. Patient’s body composition analysis
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